SCHEMBL2648632

SCHEMBL2648632

CCOC(=O)C1(NS(=O)(=O)c2cnc(N)s2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.43
PLAT P00750 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
SLC6A3 Q01959 1/20 0.35
SLC8A1 P32418 1/20 0.35
MEN1 O00255 2/20 0.33
MAPK1 P28482 2/20 0.33
KMT2A Q03164 2/20 0.33
F10 P00742 1/20 0.33
GABRA1 P14867 1/20 0.32
HSD17B10 Q99714 2/20 0.32
KDM4E B2RXH2 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2649237 0.83 ADORA3 (0.36) PLAUPLATSMN1; SMN2ADORA3SLC6A3
SCHEMBL969319 0.77 PLAU (0.40) PLAUPLATPSEN1PSEN2APH1B
SCHEMBL1240657 0.75 SMN1; SMN2 (0.53) SMN1; SMN2ADORA3SLC6A3MEN1KMT2A
SCHEMBL1241669 0.73 SMN1; SMN2 (0.51) SMN1; SMN2ADORA3SLC6A3MEN1KMT2A
SCHEMBL20656522 0.70 SMN1; SMN2 (0.41) SMN1; SMN2ADORA3SLC6A3MEN1MAPK1
Hydrochloric Acid SCHEMBL29553290 0.69 SMN1; SMN2 (0.41) SMN1; SMN2MEN1MAPK1KMT2AHSD17B10
SCHEMBL20839223 0.69 PLAU (0.38) PLAUPLATSMN1; SMN2POLBFPR2
SCHEMBL16422646 0.68 HPGD (0.36) PLAUPLATSMN1; SMN2KMT2APOLB
SCHEMBL16422587 0.68 HPGD (0.36) PLAUPLATSMN1; SMN2KMT2AHSD17B10
SCHEMBL14026302 0.67 ADAMTS5 (0.50) SMN1; SMN2ADORA3SLC6A3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582769-B2 Dicycloalkyl urea glucokinase activators NOVO NORDISK A/S (DK) 2009-09-01 US disclosed
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-05-07 US disclosed
CN-101258137-A Dicycloalkyl urea glucokinase activators NOVO NORDISK AS (DK) 2008-09-03 CN disclosed
EP-1904466-A1 DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS Novo Nordisk A/S (DK) 2008-04-02 EP disclosed
WO-2007006760-A1 DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators GCK, GCKR, UCK2 PLAU 405/4885PLAT 1121/4885SMN1; SMN2 4814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.